NO910209L - Fremgangsmaate for fremstilling av rekombinante humane anti-cd18-antistoffer. - Google Patents

Fremgangsmaate for fremstilling av rekombinante humane anti-cd18-antistoffer.

Info

Publication number
NO910209L
NO910209L NO91910209A NO910209A NO910209L NO 910209 L NO910209 L NO 910209L NO 91910209 A NO91910209 A NO 91910209A NO 910209 A NO910209 A NO 910209A NO 910209 L NO910209 L NO 910209L
Authority
NO
Norway
Prior art keywords
antibodies
procedure
preparation
recombinant human
human anti
Prior art date
Application number
NO91910209A
Other languages
English (en)
Other versions
NO910209D0 (no
Inventor
Ming-Fan Law
Iii George E Mark
John A Schmidt
Irwin I Singer
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO910209D0 publication Critical patent/NO910209D0/no
Publication of NO910209L publication Critical patent/NO910209L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO91910209A 1990-01-19 1991-01-18 Fremgangsmaate for fremstilling av rekombinante humane anti-cd18-antistoffer. NO910209L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46769290A 1990-01-19 1990-01-19
US62742290A 1990-12-20 1990-12-20

Publications (2)

Publication Number Publication Date
NO910209D0 NO910209D0 (no) 1991-01-18
NO910209L true NO910209L (no) 1991-07-22

Family

ID=27042144

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91910209A NO910209L (no) 1990-01-19 1991-01-18 Fremgangsmaate for fremstilling av rekombinante humane anti-cd18-antistoffer.

Country Status (11)

Country Link
EP (1) EP0440351A3 (no)
JP (1) JPH0654698A (no)
KR (1) KR910014505A (no)
AU (1) AU635996B2 (no)
CA (1) CA2034574A1 (no)
FI (1) FI910272A7 (no)
IE (1) IE910178A1 (no)
IL (1) IL97005A0 (no)
NO (1) NO910209L (no)
NZ (1) NZ236792A (no)
PT (1) PT96509A (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438312A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (en) * 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
WO1994002175A1 (en) * 1992-07-16 1994-02-03 Icos Corporation Alleviation of symptoms associated with inflammatory disease states
US5854070A (en) * 1992-07-16 1998-12-29 Icos Corporation Murine and humanizer 23F2G antibodies and cell lines expressing said antibodies
KR100371784B1 (ko) * 1992-12-01 2003-07-22 프로테인 디자인랩스, 인코포레이티드 L-셀렉틴과반응성인인체화된항체
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
AU5732694A (en) * 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
DK0941344T3 (da) * 1996-11-27 2004-09-27 Genentech Inc Humaniserede anti-CD11a-antistoffer
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
ATE448306T1 (de) 2000-09-01 2009-11-15 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
EP0438312A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies

Also Published As

Publication number Publication date
IE910178A1 (en) 1991-07-31
AU635996B2 (en) 1993-04-08
CA2034574A1 (en) 1991-07-20
NZ236792A (en) 1993-05-26
EP0440351A2 (en) 1991-08-07
JPH0654698A (ja) 1994-03-01
IL97005A0 (en) 1992-03-29
EP0440351A3 (en) 1992-07-01
AU6984391A (en) 1991-07-25
FI910272L (fi) 1991-07-20
FI910272A7 (fi) 1991-07-20
PT96509A (pt) 1991-10-31
KR910014505A (ko) 1991-08-31
NO910209D0 (no) 1991-01-18
FI910272A0 (fi) 1991-01-18

Similar Documents

Publication Publication Date Title
NO910209D0 (no) Fremgangsmaate for fremstilling av rekombinante humane anti-cd18 antistoffer.
NO913234D0 (no) Fremgangsmaate for fremstilling av pyrazolderivater.
FI924819A7 (fi) Ihmiskäyttöön sopivat kimeeriset anti-ICAM-1-vasta-aineet, menetelmät niiden valmistamiseksi ja niiden käyttö
NO905255D0 (no) Fremgangsmaate for fremstilling av heterocyklisk substituerte acylaminotiazoler.
NO911591L (no) Fremgangsmaate for fremstilling av sukrose-6-ester.
NO912411D0 (no) Fremgangsmaate for fremstilling av bicykliske heterocykliske forbindelser.
NO912346L (no) Fremgangsmaate for fremstilling av aminobenzodiazepiner.
NO913008D0 (no) Fremgangsmaate for fremstilling av fenylacetamid-derivater.
NO870476L (no) Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.
NO911122D0 (no) Fremgangsmaate for fremstilling av antihyperkolesterolemiske midler.
NO911065L (no) Fremgangsmaate for fremstilling av lipopeptidderivater.
NO894649D0 (no) Fremgangsmaate for fremstilling av (s)-alfa-ethyl-2-oxo-1-pyrrolidinacetamid.
NO913360L (no) Fremgangsmaate for fremstilling av syntesegass.
NO911200L (no) Fremgangsmaate for fremstilling av selektive adenosin-receptor midler.
NO893794L (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
DK69690D0 (da) Humane anti-rh(d) monoklonale antistoffer
NO913692L (no) Fremgangsmaate for fremstilling av karbapenemforbindelser.
NO911778L (no) Fremgangsmaate for fremstilling av legeringer inneholdendemg2si.
DK69590D0 (da) Humane anti-rh(d) monoklonale antistoffer
NO912979L (no) Fremgangsmaate for fremstilling av 2-(9-fluorenoyl)-carbapenederivater.
MX24596A (es) Derivado de 1-piridilimidazol y procedimiento parasu preparacion.
NO911672L (no) Fremgangsmaate for fremstilling av alkansulfonanilid-derivater.
NO893857D0 (no) Framgangsmaate for framstilling av en alkenylgruppe-innholdende organopolysiloksan.
NO893796D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO893795L (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.